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Therapeutic resistance to anti-viral drugs via mutation 
is a major challenge affecting both human and veterinary 
medicine. Following the discovery of the human 
immunodeficiency virus (HIV), this single disease alone has 
caused over 25 million deaths worldwide, with over 34 million 
people currently infected,1 highlighting the unique challenge in 
this research area. Amongst non-human vertebrates, feline 
immunodeficiency virus (FIV) infection in cats is perhaps the 
closest biological model of HIV infection with an analogous 
AIDS-like progression,2 although infection primarily occurs 
through biting and reproduction with about 11% of cats currently 
infected worldwide.3 FIV and HIV are closely related to other 
lentiviruses including the simian (SIV) and equine (EIAV) 
variants,4,5 each of which is a species-specific virus using 
analogous proteins in the viral life cycle.  
The nucleocapsid protein of FIV is a short basic nucleic 
acid binding protein, which contains two key zinc finger domains 
based on the peptide unit C-X2-C-X4-H-X4-C (CCHC) that is 
found in nearly all retroviruses.6-10 The nucleocapsid protein is 
implicated in both early (DNA synthesis and integration) and late 
phases (genomic RNA selection, dimerisation, packaging and 
budding) of viral replication.10-12 Mutagenesis studies have 
clearly demonstrated that transcription errors in this key protein 
are not tolerated and deletion or modification of either zinc finger 
leads to virus inactivation.13,14 Current approaches towards the 
development of compounds that target the nucleocapsid protein 
have focused on small molecules that sequester the Zn2+ ion from 
within the zinc finger core. These compounds are able to achieve 
this with high affinity in protein based assays (Fig. 1).15-20  
 
Figure 1 - Previously reported NCp7 targeting small molecules. 
Despite the promising activities displayed by a number 
of these compounds, several have shown unacceptable levels of 
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toxicity and as such, the search for new chemical entities against 
this mutation resistant target continues.15-20 Herein we describe 
the development of a novel series of compounds with low 
toxicity and high potency that were selected for their potential to 
target the nucleocapsid protein in FIV, as part of our longer-term 
goal of developing mutation-resistant therapeutics against HIV.15  
Previous reported agents against the nucleocapsid 
protein have been shown to cause inhibition, by covalent 
modiﬁcation of the zinc ﬁngers in NCp7, leading to zinc ejection 
and ultimately, inactivation of protein function.15-20 The 
electrophilic center plays a key role in compound activity and we 
were intrigued by the possibility of developing novel agents 
based around scorpionine derivatives 8a and 9 (Fig. 2); which 
contain two disulfide moieties that could potentially target the 
nucleocapsid of FIV in the first instance and ultimately lead to 
novel mutation resistant drugs against HIV.  
 
 
 
Figure 2 - Comparison of molecules 8a (A) with octahedral binding (C) 
and 9 (B) with tetrahedral binding (D) upon Zinc (Zn2+) binding. 
Optimized gas phase geometries using Gaussian 09 software.21 
 
We initially developed a homology model of the 
nucleocapsid protein of FIV, based on the published structure of 
the NCp7 protein of HIV, to enable us to investigate whether we 
could treat FIV via this protein target, by Zn2+ ejection (Fig. 3).22 
 
Figure 3 - Putative Zinc abstraction from a homology model of NCp7 by 
compound 8a.21 
Our proposed mechanism of action is based on 
nucleophilic attack on the Zn-S bond, by a form of redox reaction 
between the cysteine groups followed by successful chelation and 
ejection leading to protein dysfunction as outlined above (Fig. 3). 
The scorpionine core 8a is ideal, as it potentially obviates the 
need for a second molecule in our proposed mechanism as it has 
the required number of functionalities for tetrahedral 
coordination around the Zn2+ atom. This would potentially lead to 
a lower dose requirement and a higher potency compound.2,23  
The synthesis of the scorpionine core 8a, involves a 
multi-step process and poses a synthetic challenge. Reacting N-
ethyldiisopropylamine derivatives such as 7a with a disulfur 
dichloride/DABCO complex is one way to achieve this under 
mild conditions. The reaction can produce scorpionine 8a in good 
yield (40%), with surprising control.24-27 The one pot conversion 
is surprisingly scalable with the correct conditions, especially 
considering the proposed eleven conversion step process 
involved. Disulfur dichloride was added dropwise to a solution of 
N-ethyldiisopropylamine dervatives 7a-b and DABCO at -40 oC 
in 1,2-dichloroethane/chloroform and stirred for 15 min at -40 oC, 
then at room temperature for 3 days and a further 2 hours at 
reflux to produce 8a-b. The product 8a can then be further 
manipulated by suspension in xylene at reflux for 30 minutes to 
extrude the central sulfur atom and produce 9.28 Considering the 
polar nature of the assay medium involved we converted 
compound 8b into the corresponding carboxylic acid 10 with the 
aim of increasing solubility.27 
The original disulfur dichloride/DABCO reaction can 
be manipulated to produce different products by a change of 
solvent26 and the addition of formic acid or cyclopenten-1-
ylacetic acid.29 Switching from 1,2-dichloroethane to THF with 
the addition of formic acid or cyclopenten-1-ylacetic acid 
allowed the furnishing of compounds containing two oxygen 
atoms 11a-c27-30 and one oxygen atom and one sulfur atom 12a-b 
with reasonable selectivity, from the corresponding reactants 7a-
c. Compound 11b was then also suspended in xylene at reflux for 
18 hours to extrude the central sulfur and produce 13. This 
synthetic strategy allowed us to synthesize a number of 
derivatives as outlined in Scheme 1 exploring the core of 
scorpionine 8a.  
 
 
Scheme 1 - Formation of bis[1,2]dithiolo[1,4]thiazine and 
bis[1,2]dithiolopyrrole derivatives. Reagents and conditions: (a) 
S2Cl2/DABCO - 40 
oC to reflux, 8a - 1,2-dichloroethane, 40%, 8b -CHCl3, 
13%: (b) xylene, reflux, 1 h, >99%; (c) H2SO4, 60
oC, 1 h, 93%; (d) 
S2Cl2/DABCO -40 
oC to reflux, formic acid, 11a - CH2Cl2, 42%, 11b - 
CHCl3, 30%, 11c - CHCl3, 29%;
30 (e) S2Cl2/DABCO -40 
oC to reflux, 12a-
THF, cyclopenten-1-ylacetic acid, 42% 12b - CHCl3, formic acid, 13%; (f) 
xylene, reflux, 18 h, >99%. 
 
Biological testing was split into two stages, the first 
assay ruling out medium compound toxicity effects, with a short 
screen over 24 hours at three higher concentrations (100 μM - 1 
μM) exposing the compounds to the Crandell Rees Feline Kidney 
cell line (CrFK), with the second assay giving an enhanced 
toxicity and anti-FIV profile. This assay was carried out over 
seven days at six concentrations ranging between 100 μM and 1 
nM, exposing the compounds to an IL-2 independent feline 
lymphoblastoid cell line (FL-4). The different toxicity profiles 
between cell lines can be accounted for by the different exposure 
intervals and the susceptibility of the cell line to the compounds.  
The 24-hour assay rules out any major toxicity issues, 
which is key, as cytotoxic compounds removed at an early stage 
can prevent false positives and later development of toxic core 
structures. Compounds that passed the initial 24-hour exposure 
test with reasonable viabilities in CrFK cells of >75% at 10 μM 
were then screened against FIV, with an MTT assay used to 
quantify the level of cell viability.31,32 
The second phase of testing exposed the compounds to 
FL-4 cells over a period of seven days, with sampling every day 
and at each concentration (100 μM-1 nM serial dilution (x10)). 
Viral RNA was isolated from supernatants in a MagNA Pure LC 
System using the Total Nucleic Acid Isolation Kit (Roche 
Applied Science) and was subsequently used to determine the 
viral load by a quantitative real-time reverse-transcription 
polymerase chain reaction (RT-qPCR) for FIV RNA.33 The 
screening results were then checked for their viability to rule out 
any toxicity effects validating the RT-qPCR result. 
 
Table 1 - Results of cytotoxic screening and FIV viral loading assay of 
the bis[1,2]dithiolo[1,4]thiazines and bis[1,2]dithiolopyrroles  
derivatives. 
 
 
aSample concentration of compound in CrFK cells at 10μM; bGeometric 
mean, each concentration tested in triplicate after 7 days as a difference of the 
untreated cells; cCalculated using Chembiodraw ultra 12; dnot done due lack 
of improvement to toxicity profile compared to 11b en/d - Not done due to 
toxicity. 
 
The results in Table 1 clearly show that the scorpionine 
core displayed a range of activity, with compound 8a 
demonstrating excellent activity below 1 nM, with a reasonable 
ratio between the CC50 and EC50 resulting in an acceptable 
therapeutic index. Development of this initial compound led us to 
different ring systems such as 9 and 13 with differing electron 
densities in dioxothiones 11a-c and mono-substituted oxothiones 
12a-b, in the hope that some toxicity issues could be overcome 
whilst maintaining potency.  
Known anti-retroviral drugs were also tested in our 
assay, with Raltegravir displaying similar results to the reported 
values for HIV.34 AZT whilst consistent with the literature for 
FIV,35,36 displayed a surprising lack of toxicity in-vitro than that 
which is known in-vivo. This could be due to the lack of 
available enzymes in-vitro required for phosphorylation and 
activation in-vivo.36 
Modification of the core was designed to improve 
potency while reducing the toxicity seen with 8a. The 
introduction of different heteroatoms to the thione functionality 
proved key - changing from sulphur to oxygen atoms appears to 
be more toxic in 8a to 11a, but mono-substitution as in 12a gave 
some improvement in toxicity. This was broadly true for the 
longer toxicity screen with two oxygen atom substitutions, 
proving too toxic to be worth screening further than the initial 
assay. 
Despite modification, the original scorpinine compound 
8a proved the most potent compound, but exploration of the 
toxicity profile via 11a-11c and 13 showed that double oxygen 
atom substitution proved unworthy of further investigation. 11b 
was slightly less toxic than 8a, but the potency also dropped, 
whilst the equivalent mono substituted compound 12b had better 
toxicity with a CC50 of 2.27 μM, but had the same therapeutic 
index of 3.5, so had actually made little improvement.  Reducing 
the ring size of 11b to 13 also showed no improvement in the 
initial toxicity screen and so was not tested further. A surprising 
result was that 12a showed similar potency to 10, as it was 
anticipated that a carboxylic acid would be superior to an ester 
due to the enhanced solubility and reduced cLogP. The 
compound with the most promise was 9; the decreased ring size 
clearly had an effect on the toxicity unlike 13. The activity of 9 
was lower than 8a, but the increased therapeutic window partially 
compensated for this. This could also be attributed to the gas 
phase data that shows octahedral binding for 8a and tetrahedral 
for 9. 
The progression from day one to day seven showed a 
marked decrease in viral loads in the supernatant and hence less 
virion shedding, as exposure of the cells continued. We observed 
a full spectrum of results from inactive/toxic at high 
concentration to highly active/non-toxic at low concentration. 
False positives were ruled out via toxicity screening, which 
validated the idea that the compounds can actively reduce the 
amount of virus shed from cells. This means application of the 
compounds to cells, slows down viral replication and decreases 
viral load. In the seven-day screening we saw significant viral 
reduction that was independent of toxicity.  
Overall, the screening has shown that the scorpionine 
core is able to reduce viral loading and that it is a viable 
therapeutic target against the nucleocapsid protein of FIV that 
warrants further development. We have also shown that the 
diketothione was far more potent than the oxothione as it 
mitigates the toxicity concerns. We have also demonstrated that 
moving to a 5+5+5 scaffold over the initial 5+6+5 heterocyclic 
system appears to be favorable with increased potency and ligand 
efficiency while reducing toxicity. Compound 9 clearly show that 
this compound class has potential, with high activity and a 
reasonable therapeutic window. Investigations into this class 
continue with the aim of generating a pre-clinical candidate that 
can treat both FIV and HIV and will be reported in due course. 
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